Wednesday, July 8, 2026

pharma · Dravet Syndrome · Dravet syndrome · STOK

Stoke Therapeutics

Stoke Therapeutics clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Bedford, USA HQ
2017 Founded
205 Employees
Public company Type
STOK · NYSE Ticker
Company details
Status
Public
HQ
Bedford, USA
Founded
2017
Employees
205
Programs
8
Drugs
4
Patents
14
Intelligence · Clinical Programs

Stoke Therapeutics projects

3 ClinicalTrials.gov programs sponsored by Stoke Therapeutics.

Stoke Therapeutics has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Milrinone

    Stoke Therapeutics

    Valvular Stenosis

    phase 2 small molecule completed

    1 trial
  2. STK-001 - Single Ascending Doses

    Stoke Therapeutics

    Dravet Syndrome

    phase 2 small molecule completed

    1 trial
  3. zorevunersen (STK-001)

    Stoke Therapeutics

    Dravet Syndrome

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Stoke Therapeutics have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.